glp-1 news 2025 october 9 trends 2025: real-world data, patient outcomes & future therapies FDA issued 25 warning letters

Clinical experience from thousands of patients in optimization medicine practices supports its use, but the formal evidence lags behind the clinical adoption

8 # #tiktok #tiktok # #inzent 1 HOW TO 7261 .. 70-72 40 2-3 82 WHERY WELL

Goodman & Gilmans The Pharmacological Basis of Therapeutics

Current FDA labeling for semaglutide products includes warnings or precautions involving: Acute pancreatitis Acute gallbladder disease Acute kidney injury due to volume depletion Severe gastrointestinal reactions Hypoglycemia when combined with insulin or insulin secretagogues Diabetic retinopathy complications in susceptible patients Serious hypersensitivity reactions Pulmonary aspiration risk during general anesthesia or deep sedation Semaglutide labeling also contains a boxed warning regarding thyroid C-cell tumors observed in rodents

Writing - original draft: GB, AD, EB, MH